Abbott to acquire Exact Sciences
Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.
Together, the companies will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages.
Exact Sciences focuses on the early detection of cancer and supporting personalized treatments. Exact Sciences’ comprehensive product offerings support patients and their healthcare providers before, during and after a cancer diagnosis. The company is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence.
Its product offerings include the Cologuard® test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX®, which informs personalized treatment decisions for patients with breast cancer; Oncodetect™, which identifies molecular residual disease (MRD) to help assess the risk of recurrence and guide follow-up care; and Cancerguard™, a multi-cancer early detection blood test.
CME Corp announces key operations executives elevated to vice president roles
CME Corp. has promoted three senior operations leaders to Vice President positions, expanding the executive leadership team as part of the company’s ongoing growth strategy. The promotions include Kelli Bugbee (now Vice President, Administrative Operations), Daniel Chevrette (Vice President, Service Solutions), and Wade Oliveira (Vice President, Distribution Operations). These appointments recognize their expanded responsibilities across administrative support, delivery/biomedical services, and logistics/distribution, reflecting CME’s commitment to operational excellence and customer service amid nationwide expansion. According to leadership, the changes align with CME’s strategic vision to enhance internal alignment and strengthen service delivery for healthcare and life-sciences clients across the U.S.
Cardinal Health certified as a Great Place to Work
Cardinal Health has received Great Place to Work Certification in six countries, including the U.S., Canada, Mexico, India, Puerto Rico and the Philippines. Great Place to Work evaluates workplace culture and employee experience based on employees’ perspectives. The company works with tens of thousands of employers around the globe and uses employee data to identify and showcase top places to work.
The Great Place to Work Certification is based on a rigorously developed employee survey that is considered by leaders a standard for quantifying the return on investment of workplace culture. Its employee engagement survey gathers feedback focused on trust, respect and camaraderie. Employees’ real-life experiences at work determine whether a company earns the Great Place to Work Certification. Across the six countries we selected to be considered for the Certification, 85% of surveyed employees said that Cardinal Health is a great place to work.